Expert Hails NRG1 Fusions as the "Next Big Target" in Oncology
NRG1 fusions occur in low frequency across solid tumors, and because these alterations can evade traditional sequencing modalities, RNA-based next-generation sequencing is imperative.
Dr. Duruisseaux on the Incidence of NRG1 Fusions in Solid Tumors
Michaël Duruisseaux, MD, a medical oncologist at Lyon Cancer Institute in France, discusses the incidence of NRG1 fusions in solid tumors.
Dr. Liu on NRG1 Fusions in Oncology
Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the prevalence of NRG1 fusions in oncology.
Case Series Highlights Afatinib Activity in NRG1+ Cancers
A case series presented at the 2019 ESMO Congress highlighted the activity of afatinib in patients with NRG1-positive tumors.
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma
Khaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.
Dr. Tolba on Targeting NRG1 Fusions With Afatinib
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the potential to target NRG1 fusion–positive lung adenocarcinoma with afatinib (Gilotrif).
Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain
Early data suggest that afatinib (Gilotrif) is a potentially effective treatment option for patients with lung adenocarcinoma who have NRG1 fusions, but the identification of these fusions continues to pose a challenge.
Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer
Findings from a small case series of patients with lung cancer added to evidence that afatinib is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions.
Afatinib Shows Potential in NRG1-Positive Gastrointestinal Cancers
Benjamin Weinberg, MD, provides insight into NRG1 fusions, the effectiveness of afatinib in patients harboring these fusions, and future research being done in NRG1 fusion–positive gastrointestinal cancers.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512